The Amyloid-β Pathway in Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 412 of the 418 references it cites were found in a registry or an index.
Abstract
Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the center of Alzheimer’s disease (AD) pathophysiology. While the detailed molecular mechanisms of the pathway and the spatial-temporal dynamics leading to synaptic failure, neurodegeneration, and clinical onset are still under intense investigation, the established biochemical alterations of the Aβ cycle remain the core biological hallmark of AD and are promising targets for the development of disease-modifying therapies. Here, we systematically review and update the vast state-of-the-art literature of Aβ science with evidence from basic research studies to human genetic and multi-modal biomarker investigations, which supports a crucial role of Aβ pathway dyshomeostasis in AD pathophysiological dynamics. We discuss the evidence highlighting a differentiated interaction of distinct Aβ species with other AD-related biological mechanisms, such as tau-mediated, neuroimmune and inflammatory changes, as well as a neurochemical imbalance. Through the lens of the latest development of multimodal in vivo biomarkers of AD, this cross-disciplinary review examines the compelling hypothesis- and data-driven rationale for Aβ-targeting therapeutic strategies in development for the early treatment of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Traditional neuropathological phases of amyloid-β deposition in Alzheimer’s disease dementia. Red areas in Phase 1 depicts the cortical regions with the initial accumulation of amyloid-β during the early pre-clinical stage. Continued deposition in the same areas are shown in darker colors in the subsequent stages, with the new areas showing amyloid-β in red in each phase. Neocortical regions with the early accumulation of amyloid-β in phase 1 include association cortices. Additional accumulation is seen in allocortical regions and midbrain (phases 2 and 3), with the cerebellum and brain stem having amyloid-β accumulation in late phase clinical stages. The change to darker shading indicates the continuous accumulation of Aβ. Adapted with permission from ref. [13].](https://figures.cochat.ai/paper-figures/e5a44d70ea1143e09c5f08774401df5b/the-amyloid-pathway-in-alzheimers-disease-figure-1.jpg)
![Fig. 2 Hypothetical biomarker evidence-driven model of AD pathophysiology. Hypothetical model of dynamic biomarkers of the AD is expanded to explicate the preclinical phase. Aβ is identified by cerebrospinal fluid Aβ42 assay or PET amyloid imaging. Synaptic dysfunction evidenced by [18F]-fluorodeoxyglucose positron emission tomography (FDG-PET) or functional magnetic resonance imaging (fMRI), with a dashed yellow line to indicate that synaptic dysfunction may be detectable in carriers of the ε4 allele of the apolipoprotein E gene before detectable Aβ deposition. Neuronal injury is evidenced by cerebrospinal fluid tau or phospho-tau, and brain structure is documented by structural magnetic resonance imaging. Biomarkers change from normal to maximally abnormal (y-axis) as a function of disease stage (x-axis). The temporal trajectory of two key indicators used to stage the disease clinically, cognitive and behavioral measures, and clinical function are also illustrated. Neurofilament light chain (NfL) and neurogranin are newer and potentially more accurate markers of neuronal injury. Figure adapted with permission from ref. [391].](https://figures.cochat.ai/paper-figures/7ed46c7c8b734383b369c38cdc5d4822/the-amyloid-pathway-in-alzheimers-disease-figure-2.jpg)
![Fig. 3 Amyloidogenic vs non-amyloidogenic pathway. Amyloid Precursor Protein (APP) is a single transmembrane protein. For the non-amyloidogenic pathway (left), APP is cleaved by A Disintegrin And Metalloprotease (ADAM) family proteases to yield the membrane-tethered C83 fragment and extracellularly released soluble APP alpha (sAPPα). In the amyloidogenic pathway (right), APP is first cleaved by β-secretase (β-APP-cleaving enzyme-1 or BACE1). CTF-β fragment is subsequently cleaved by γ-secretase composed of Presenilin 1 or 2, Nicastrin, PEN2 and APH-1. This proteolytic processing releases amyloid-β into the extracellular space. APP intracellular domain (AICD) from the initial β-secretase cleavage is released into intracellular space. Adapted with permission from ref. [392].](https://figures.cochat.ai/paper-figures/3740698a98f94719afb3e59ce7300d58/the-amyloid-pathway-in-alzheimers-disease-figure-3.jpg)
![Fig. 4 Amyloid-β aggregation species and evidence of reversible states: the amyloid-β cycle. Aggregation species of Aβ can exist as monomers, dimers, oligomers, protofibril, fibril and amyloid plaques. These species exist in steady state where one form can convert to another in a bidirectional manner. The species are characterized by aggregate size, conformation state and solubility, with fibril and amyloid plaque being insoluble. Adapted with permission from ref. [108].](https://figures.cochat.ai/paper-figures/8538bb3315fc441bbf40d52f125a53d6/the-amyloid-pathway-in-alzheimers-disease-figure-4.jpg)
![Fig. 5 The evidence-driven experimental model of Aβ-tau synergy. Accumulation of neurofibrillary tangles made up of tau (red) and amyloid plaques composed of amyloid-β (blue) coincides in the neocortical areas in the brain of Alzheimer’s disease subjects supporting amyloid-β dependent tau propagation across neocortical regions. Inter-neuronal spreading of tau (bottom) is enhanced in AD brains with both plaques and tangle build-up. Adapted with permission from ref. [221].](https://figures.cochat.ai/paper-figures/fceb1804d6ff427492bb8c0f5ea813ec/the-amyloid-pathway-in-alzheimers-disease-figure-5.jpg)
![Fig. 6 Techniques of in vivo Alzheimer’s disease amyloid-β pathway staging, along the clinical continuum, based on molecular imaging and innovative algorithms. Neocortical distribution of [18F]-florbetapir is shown in a composite representation according to Aβ stages. Early composite (positive in stage 1 in green; left), intermediate composite (positive in stage 2 in blue; middle) and late composite (positive in stage 3 in red; right) can allow global and regional assessment of amyloid plaque deposition. Adapted with permission from: ref. [393].](https://figures.cochat.ai/paper-figures/258ac97d751b433293cf5d46f21104f9/the-amyloid-pathway-in-alzheimers-disease-figure-6.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Biomarkers play a crucial role in patient selection, biological effect detection, dose optimization, and monitoring response progress, with recent approvals of Aβ monoclonal antibodies benefiting from new and accurate biomarkers.83,423”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [83]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Aβ originates from the processing of the amyloid precursor protein (APP) through sequential cleavage by β-secretase and γ-secretase, resulting in various lengths of Aβ fragments, with Aβ40 and Aβ42 being predominant.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The hydrophobic C-terminus of Aβ42 facilitates its aggregation and the formation of senile plaques.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutations in presenilin-1 (PS1) can promote Aβ accumulation through increased production and impaired autophagy functions.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As AD progresses to its late stages, the effectiveness of nanoparticle-based therapies often diminishes due to the increased disruption of the BBB [148].”
From Targeted Nanoparticles for Drug Delivery Across the Blood–Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review (2026) · cites this paper as [149]
Experimental — accuracy not yet measured
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–400 of 412
Dynamics of oligomer populations formed during the aggregation of Alzheimer’s Aβ42 peptide
Michaels, T. C. T., Šarić, A., Curk, S., Bernfur, K., Arosio, P., Meisl, G., Dear, A. J., Cohen, S. I. A., Dobson, C. M., Vendruscolo, M., et al. (2020) · Nature Chemistry · doi:10.1038/s41557-020-0452-1 · Cited by 339
Self-citationMormino, E. C., Smiljic, A., Hayenga, A. O., H. Onami, S., Greicius, M. D., Rabinovici, G. D., Janabi, M., Baker, S. L., V. Yen, I., Madison, C. M., et al. (2011) · Cerebral Cortex · doi:10.1093/cercor/bhr025 · Cited by 336
The role of astroglia in Alzheimer's disease: pathophysiology and clinical implications
Arranz, A. M., & De Strooper, B. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30490-3 · Cited by 334
Developing the ATX(N) classification for use across the Alzheimer disease continuum
Hampel, H., Cummings, J., Blennow, K., Gao, P., Jack, C. R., & Vergallo, A. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00520-w · Cited by 327 · cited 2×
“Such trickle-down effects comprise the initiating factor of brain Aβ accumulation as an early and central pathophysiological alteration within the AD biological continuum [7, 15, 17].”
BackgroundSelf-citationLoss-of-function variants in ABCA7 confer risk of Alzheimer's disease
DemGene, Steinberg, S., Stefansson, H., Jonsson, T., Johannsdottir, H., Ingason, A., Helgason, H., Sulem, P., Magnusson, O. T., Gudjonsson, S. A., et al. (2015) · Nature Genetics · doi:10.1038/ng.3246 · Cited by 324
Self-citationAssociation of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals
Sperling, R. A., Donohue, M. C., Raman, R., Sun, C.-K., Yaari, R., Holdridge, K., Siemers, E., Johnson, K. A., Aisen, P. S., & for the A4 Study Team (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.0387 · Cited by 324
Self-citationSenile plaque neurites in Alzheimer disease accumulate amyloid precursor protein.
Cras, P., Kawai, M., Lowery, D., Gonzalez-DeWhitt, P., Greenberg, B., & Perry, G. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.17.7552 · Cited by 319
Self-citationStreit, W. J., Xue, Q.-S., Tischer, J., & Bechmann, I. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0142-6 · Cited by 317
Subjective cognitive decline and risk of MCI: The Mayo Clinic Study of Aging
van Harten, A. C., Mielke, M. M., Swenson-Dravis, D. M., Hagen, C. E., Edwards, K. K., Roberts, R. O., Geda, Y. E., Knopman, D. S., & Petersen, R. C. (2018) · Neurology · doi:10.1212/wnl.0000000000005863 · Cited by 312
Lipids revert inert Aβ amyloid fibrils to neurotoxic protofibrils that affect learning in mice
Martins, I. C., Kuperstein, I., Wilkinson, H., Maes, E., Vanbrabant, M., Jonckheere, W., Van Gelder, P., Hartmann, D., D'Hooge, R., De Strooper, B., et al. (2008) · The EMBO Journal · doi:10.1038/sj.emboj.7601953 · Cited by 311
Kim, J., Castellano, J. M., Jiang, H., Basak, J. M., Parsadanian, M., Pham, V., Mason, S. M., Paul, S. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.11.013 · Cited by 308
Amyloid‐beta oligomerization in Alzheimer dementia versus high‐pathology controls
Esparza, T. J., Zhao, H., Cirrito, J. R., Cairns, N. J., Bateman, R. J., Holtzman, D. M., & Brody, D. L. (2013) · Annals of Neurology · doi:10.1002/ana.23748 · Cited by 306
Apolipoprotein E–dependent accumulation of Alzheimer disease–related lesions begins in middle age
Kok, E., Haikonen, S., Luoto, T., Huhtala, H., Goebeler, S., Haapasalo, H., & Karhunen, P. J. (2009) · Annals of Neurology · doi:10.1002/ana.21696 · Cited by 299
[Apolipoprotein E polymorphism and Alzheimer disease].
van der Weide, J., Steijns, L. S. W., Jl, T., Wj, N., & Klaverwijden, G. (1996) · PubMed · Cited by 297
Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers
Initiative, T. A. D. N., Landau, S. M., Thomas, B. A., Thurfjell, L., Schmidt, M., Margolin, R., Mintun, M., Pontecorvo, M., Baker, S. L., & Jagust, W. J. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2753-3 · Cited by 294
Sadleir, K. R., Kandalepas, P. C., Buggia-Prévot, V., Nicholson, D. A., Thinakaran, G., & Vassar, R. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1558-9 · Cited by 294
Wang, L., Benzinger, T. L., Su, Y., Christensen, J., Friedrichsen, K., Aldea, P., McConathy, J., Cairns, N. J., Fagan, A. M., Morris, J. C., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.2078 · Cited by 293
Sensitive ELISA detection of amyloid‐β protofibrils in biological samples
Englund, H., Sehlin, D., Johansson, A., Nilsson, L. N. G., Gellerfors, P., Paulie, S., Lannfelt, L., & Pettersson, F. E. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04759.x · Cited by 292
Self-citationNovel Alzheimer risk genes determine the microglia response to amyloid-β but not to TAU pathology
Sierksma, A., Lu, A., Mancuso, R., Fattorelli, N., Thrupp, N., Salta, E., Zoco, J., Blum, D., Buée, L., De Strooper, B., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201910606 · Cited by 291
Down syndrome and Alzheimer's disease: common pathways, common goals
Hartley, D., Blumenthal, T., Carrillo, M., DiPaolo, G., Esralew, L., Gardiner, K., Granholm, A.-C., Iqbal, K., Krams, M., Lemere, C., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.10.007 · Cited by 290
In vivo staging of regional amyloid deposition
Grothe, M. J., Barthel, H., Sepulcre, J., Dyrba, M., Sabri, O., Teipel, S. J., Stern, Y., & Initiative, A. D. N. (2022) · DZNE Pub · doi:10.7916/0vj1-4c02 · Cited by 289
Rice, H. C., de Malmazet, D., Schreurs, A., Frere, S., Van Molle, I., Volkov, A. N., Creemers, E., Vertkin, I., Nys, J., Ranaivoson, F. M., et al. (2019) · Science · doi:10.1126/science.aao4827 · Cited by 281
Neuronal Clearance of Amyloid-β by Endocytic Receptor LRP1
Kanekiyo, T., Cirrito, J. R., Liu, C.-C., Shinohara, M., Li, J., Schuler, D. R., Shinohara, M., Holtzman, D. M., & Bu, G. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.3487-13.2013 · Cited by 280
Tucker, S., Möller, C., Tegerstedt, K., Lord, A., Laudon, H., Sjödahl, J., Söderberg, L., Spens, E., Sahlin, C., Waara, E. R., et al. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-140741 · Cited by 272
Self-citationHigh‐molecular‐weight β‐amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients
Fukumoto, H., Tokuda, T., Kasai, T., Ishigami, N., Hidaka, H., Kondo, M., Allsop, D., & Nakagawa, M. (2010) · The FASEB Journal · doi:10.1096/fj.09-150359 · Cited by 264
Generation of amyloid β protein from its precursor is sequence specific
Citron, M., Teplow, D. B., & Selkoe, D. J. (1995) · Neuron · doi:10.1016/0896-6273(95)90323-2 · Cited by 263
Li, S., & Selkoe, D. J. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15007 · Cited by 263
Rowe, C. C., & Villemagne, V. L. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.076315 · Cited by 261 · cited 1×
“Recently, the FDA has approved fluorine-18 [(18)F]-labeled compounds—[(18)F]-Florbetapir ([(18)F]-AV-45, AmyvidTM), [(18)F]-Florbetaben ([(18)F]-FBB, NeuraceqTM), [(18)F]-Flutemetamol ([(18)F]-FMT, VizamylTM)—that have a 110-min half-life, thus allowing for centralized production and regional distribution [365, 366].”
BackgroundSelf-citationγ-Secretase Heterogeneity in the Aph1 Subunit: Relevance for Alzheimer’s Disease
Serneels, L., Van Biervliet, J., Craessaerts, K., Dejaegere, T., Horré, K., Van Houtvin, T., Esselmann, H., Paul, S., Schäfer, M. K., Berezovska, O., et al. (2009) · Science · doi:10.1126/science.1171176 · Cited by 260
Lord, A., Kalimo, H., Eckman, C., Zhang, X.-Q., Lannfelt, L., & Nilsson, L. N. G. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.12.007 · Cited by 260
Self-citationAmyloid β-Protein Dimers Rapidly Form Stable Synaptotoxic Protofibrils
O'Nuallain, B., Freir, D. B., Nicoll, A. J., Risse, E., Ferguson, N., Herron, C. E., Collinge, J., & Walsh, D. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3537-10.2010 · Cited by 259
Lopera, F. J. (1997) · JAMA · doi:10.1001/jama.277.10.793 · Cited by 255
Morris, E., Chalkidou, A., Hammers, A., Peacock, J., Summers, J., & Keevil, S. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3228-x · Cited by 248
Bis, J. C., Jian, X., Kunkle, B. W., Chen, Y., Hamilton-Nelson, K. L., Bush, W. S., Salerno, W. J., Lancour, D., Ma, Y., Renton, A. E., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0112-7 · Cited by 248
Halim, A., Brinkmalm, G., Rüetschi, U., Westman-Brinkmalm, A., Portelius, E., Zetterberg, H., Blennow, K., Larson, G., & Nilsson, J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102664108 · Cited by 246
Self-citationFleisher, A. S., Chen, K., Quiroz, Y. T., Jakimovich, L. J., Gomez, M. G., Langois, C. M., Langbaum, J. B., Ayutyanont, N., Roontiva, A., Thiyyagura, P., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70227-2 · Cited by 242
Knowles, R. B., Wyart, C., Buldyrev, S. V., Cruz, L., Urbanc, B., Hasselmo, M. E., Stanley, H. E., & Hyman, B. T. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.9.5274 · Cited by 241
Kandalepas, P. C., Sadleir, K. R., Eimer, W. A., Zhao, J., Nicholson, D. A., & Vassar, R. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1152-3 · Cited by 240
Mattsson, N., Insel, P. S., Donohue, M., Landau, S., Jagust, W. J., Shaw, L. M., Trojanowski, J. Q., Zetterberg, H., Blennow, K., & Weiner, M. W. (2015) · Brain · doi:10.1093/brain/awu367 · Cited by 237
Self-citationStaging β -Amyloid Pathology With Amyloid Positron Emission Tomography
Mattsson, N., Palmqvist, S., Stomrud, E., Vogel, J., & Hansson, O. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.2214 · Cited by 237
Amyloid accelerates tau propagation and toxicity in a model of early Alzheimer’s disease
Pooler, A. M., Polydoro, M., Maury, E. A., Nicholls, S. B., Reddy, S. M., Wegmann, S., William, C., Saqran, L., Cagsal-Getkin, O., Pitstick, R., et al. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0199-x · Cited by 236
Li, P., Marshall, L., Oh, G., Jakubowski, J. L., Groot, D., He, Y., Wang, T., Petronis, A., & Labrie, V. (2019) · Nature Communications · doi:10.1038/s41467-019-10101-7 · Cited by 234
Marzi, S. J., Leung, S. K., Ribarska, T., Hannon, E., Smith, A. R., Pishva, E., Poschmann, J., Moore, K., Troakes, C., Al-Sarraj, S., et al. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0253-7 · Cited by 232
Congo red and thioflavin‐T analogs detect Aβ oligomers
Maezawa, I., Hong, H., Liu, R., Wu, C., Cheng, R. H., Kung, M., Kung, H. F., Lam, K. S., Oddo, S., LaFerla, F. M., et al. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04972.x · Cited by 227
AMPA receptor downscaling at the onset of Alzheimer's disease pathology in double knockin mice
Chang, E. H., Savage, M. J., Flood, D. G., Thomas, J. M., Levy, R. B., Mahadomrongkul, V., Shirao, T., Aoki, C., & Huerta, P. T. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507313103 · Cited by 225
The roles of inflammation and immune mechanisms in Alzheimer's disease
Van Eldik, L. J., Carrillo, M. C., Cole, P. E., Feuerbach, D., Greenberg, B. D., Hendrix, J. A., Kennedy, M., Kozauer, N., Margolin, R. A., Molinuevo, J. L., et al. (2016) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.05.001 · Cited by 225
Untangling Genetic Risk for Alzheimer’s Disease
Pimenova, A. A., Raj, T., & Goate, A. M. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.05.014 · Cited by 223
Goedert, M. (1987) · The EMBO Journal · doi:10.1002/j.1460-2075.1987.tb02694.x · Cited by 222
Takeuchi, M., & Yamagishi, S.-I. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208784139693 · Cited by 218
Suh, J., Choi, S. H., Romano, D. M., Gannon, M. A., Lesinski, A. N., Kim, D. Y., & Tanzi, R. E. (2013) · Neuron · doi:10.1016/j.neuron.2013.08.035 · Cited by 217
Xia, W., Yang, T., Shankar, G., Smith, I. M., Shen, Y., Walsh, D. M., & Selkoe, D. J. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.565 · Cited by 216
He, X., Qin, W., Liu, Y., Zhang, X., Duan, Y., Song, J., Li, K., Jiang, T., & Yu, C. (2014) · Human Brain Mapping · doi:10.1002/hbm.22414 · Cited by 213
Morris, G. P., Clark, I. A., & Vissel, B. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1918-8 · Cited by 212
Lin, Y.-T., Seo, J., Gao, F., Feldman, H. M., Wen, H.-L., Penney, J., Cam, H. P., Gjoneska, E., Raja, W. K., Cheng, J., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.06.011 · Cited by 210
Subtyping of circulating exosome-bound amyloid β reflects brain plaque deposition
Lim, C. Z. J., Zhang, Y., Chen, Y., Zhao, H., Stephenson, M. C., Ho, N. R. Y., Chen, Y., Chung, J., Reilhac, A., Loh, T. P., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09030-2 · Cited by 209
Self-citationHypomethylation of the amyloid precursor protein gene in the brain of an alzheimer’s disease patient
West, R. L., Lee, J. M., & Maroun, L. E. (1995) · Journal of Molecular Neuroscience · doi:10.1007/bf02736773 · Cited by 208
Jack, C. R., Wiste, H. J., Botha, H., Weigand, S. D., Therneau, T. M., Knopman, D. S., Graff-Radford, J., Jones, D. T., Ferman, T. J., Boeve, B. F., et al. (2019) · Brain · doi:10.1093/brain/awz268 · Cited by 200
Buckley, R. F., Maruff, P., Ames, D., Bourgeat, P., Martins, R. N., Masters, C. L., Rainey‐Smith, S., Lautenschlager, N., Rowe, C. C., Savage, G., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.12.013 · Cited by 198
Self-citationMaloney, J. A., Bainbridge, T., Gustafson, A., Zhang, S., Kyauk, R., Steiner, P., van der Brug, M., Liu, Y., Ernst, J. A., Watts, R. J., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.589069 · Cited by 197
Eckman, E. A., Adams, S. K., Troendle, F. J., Stodola, B. A., Kahn, M. A., Fauq, A. H., Xiao, H. D., Bernstein, K. E., & Eckman, C. B. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605827200 · Cited by 196
The precursor of Alzheimer??s disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J., Masters, C., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & M??ller-Hill, B. (1987) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-198701030-00032 · Cited by 195
Self-citationAlzheimer’s Disease, Oligomers, and Inflammation
Forloni, G., & Balducci, C. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170819 · Cited by 194
Acute function of secreted amyloid precursor protein fragment APPsα in synaptic plasticity
Hick, M., Herrmann, U., Weyer, S. W., Mallm, J.-P., Tschäpe, J.-A., Borgers, M., Mercken, M., Roth, F. C., Draguhn, A., Slomianka, L., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-014-1368-x · Cited by 191
Dementia UK: Second Edition - Overview
Prince, M. J., Knapp, M. R. J., Guerchet, M., McCrone, P., Prina, M. A., Comas‐Herrera, A., Wittenberg, R., Adelaja, B., Hu, B., King, D., et al. (2014) · Research Portal (King's College London) · Cited by 190
Lewczuk, P., Lelental, N., Spitzer, P., Maler, J. M., & Kornhuber, J. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-140771 · Cited by 188
Quiroz, Y. T., Sperling, R. A., Norton, D. J., Baena, A., Arboleda-Velasquez, J. F., Cosio, D., Schultz, A., Lapoint, M., Guzman-Velez, E., Miller, J. B., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.4907 · Cited by 186
Suri, S., Heise, V., Trachtenberg, A. J., & Mackay, C. E. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.10.010 · Cited by 183
A Sensitive Aβ Oligomer Assay Discriminates Alzheimer's and Aged Control Cerebrospinal Fluid
Savage, M. J., Kalinina, J., Wolfe, A., Tugusheva, K., Korn, R., Cash-Mason, T., Maxwell, J. W., Hatcher, N. G., Haugabook, S. J., Wu, G., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.1675-13.2014 · Cited by 183
Sunderland, T., Mirza, N., Putnam, K. T., Linker, G., Bhupali, D., Durham, R., Soares, H., Kimmel, L., Friedman, D., Bergeson, J., et al. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.07.021 · Cited by 179
Grothe, M., Heinsen, H., & Teipel, S. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.10.018 · Cited by 178
Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation
Liao, F., Li, A., Xiong, M., Bien-Ly, N., Jiang, H., Zhang, Y., Finn, M. B., Hoyle, R., Keyser, J., Lefton, K. B., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96429 · Cited by 178
Brookmeyer, R., & Abdalla, N. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.03.005 · Cited by 176
Vergallo, A., Mégret, L., Lista, S., Cavedo, E., Zetterberg, H., Blennow, K., Vanmechelen, E., De Vos, A., Habert, M., Potier, M., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.03.009 · Cited by 175
Self-citationLow PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers
Schöll, M., Wall, A., Thordardottir, S., Ferreira, D., Bogdanovic, N., Långström, B., Almkvist, O., Graff, C., & Nordberg, A. (2012) · Neurology · doi:10.1212/wnl.0b013e31825fdf18 · Cited by 169
Bellenguez, C., Charbonnier, C., Grenier-Boley, B., Quenez, O., Le Guennec, K., Nicolas, G., Chauhan, G., Wallon, D., Rousseau, S., Richard, A. C., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.07.001 · Cited by 166
Diversity of Amyloid-beta Proteoforms in the Alzheimer’s Disease Brain
Wildburger, N. C., Esparza, T. J., LeDuc, R. D., Fellers, R. T., Thomas, P. M., Cairns, N. J., Kelleher, N. L., Bateman, R. J., & Brody, D. L. (2017) · Scientific Reports · doi:10.1038/s41598-017-10422-x · Cited by 164
Hong, W., Wang, Z., Liu, W., O’Malley, T. T., Jin, M., Willem, M., Haass, C., Frosch, M. P., & Walsh, D. M. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1846-7 · Cited by 163
Wardell, M. R., Brennan, S. O., Janus, E. D., Fraser, R., & Carrell, R. W. (1987) · Journal of Clinical Investigation · doi:10.1172/jci113096 · Cited by 159
APOE4-mediated amyloid-β pathology depends on its neuronal receptor LRP1
Tachibana, M., Holm, M.-L., Liu, C.-C., Shinohara, M., Aikawa, T., Oue, H., Yamazaki, Y., Martens, Y. A., Murray, M. E., Sullivan, P. M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124853 · Cited by 156
Chételat, G., Villemagne, V. L., Pike, K. E., Ellis, K. A., Bourgeat, P., Jones, G., O’Keefe, G. J., Salvado, O., Szoeke, C., Martins, R. N., et al. (2011) · Brain · doi:10.1093/brain/awq383 · Cited by 153
Self-citationChen, J.-H., Ke, K.-F., Lu, J.-H., Qiu, Y.-H., & Peng, Y.-P. (2015) · PLOS ONE · doi:10.1371/journal.pone.0116549 · Cited by 151
Microglial Gi-dependent dynamics regulate brain network hyperexcitability
Merlini, M., Rafalski, V. A., Ma, K., Kim, K.-Y., Bushong, E. A., Rios Coronado, P. E., Yan, Z., Mendiola, A. S., Sozmen, E. G., Ryu, J. K., et al. (2021) · Nature Neuroscience · doi:10.1038/s41593-020-00756-7 · Cited by 151
Grothe, M. J., Teipel, S. J., & Initiative, F. T. A. D. N. (2016) · Human Brain Mapping · doi:10.1002/hbm.23018 · Cited by 150
Wang, M. J., Yi, S., Han, J.-Y., Park, S. Y., Jang, J.-W., Chun, I. K., Kim, S. E., Lee, B. S., Kim, G. J., Yu, J. S., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0324-0 · Cited by 150
Self-citationSehlin, D., Englund, H., Simu, B., Karlsson, M., Ingelsson, M., Nikolajeff, F., Lannfelt, L., & Pettersson, F. E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032014 · Cited by 149
Self-citationRole of TGFβ signaling in the pathogenesis of Alzheimer’s disease
von Bernhardi, R., Cornejo, F., Parada, G. E., & Eugenín, J. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00426 · Cited by 149
Proteome-wide observation of the phenomenon of life on the edge of solubility
Vecchi, G., Sormanni, P., Mannini, B., Vandelli, A., Tartaglia, G. G., Dobson, C. M., Hartl, F. U., & Vendruscolo, M. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1910444117 · Cited by 148
Self-citationJanelidze, S., Pannee, J., Mikulskis, A., Chiao, P., Zetterberg, H., Blennow, K., & Hansson, O. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.2814 · Cited by 147
Self-citationPlasma Amyloid-β (Aβ42) Correlates with Cerebrospinal Fluid Aβ42 in Alzheimer’s Disease
Teunissen, C. E., Chiu, M.-J., Yang, C.-C., Yang, S.-Y., Scheltens, P., Zetterberg, H., & Blennow, K. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170784 · Cited by 144
Self-citationEvaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease
Hölttä, M., Hansson, O., Andreasson, U., Hertze, J., Minthon, L., Nägga, K., Andreasen, N., Zetterberg, H., & Blennow, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066381 · Cited by 143
Self-citationFunctional network integrity presages cognitive decline in preclinical Alzheimer disease
Buckley, R. F., Schultz, A. P., Hedden, T., Papp, K. V., Hanseeuw, B. J., Marshall, G., Sepulcre, J., Smith, E. E., Rentz, D. M., Johnson, K. A., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004059 · Cited by 142
Kadir, A., Marutle, A., Gonzalez, D., Schöll, M., Almkvist, O., Mousavi, M., Mustafiz, T., Darreh-Shori, T., Nennesmo, I., & Nordberg, A. (2011) · Brain · doi:10.1093/brain/awq349 · Cited by 140
A unifying hypothesis for Alzheimer's disease: from plaques to neurodegeneration
Edwards, F. A. (2019) · Trends in Neurosciences · doi:10.1016/j.tins.2019.03.003 · Cited by 140
Differential effects of glycation on protein aggregation and amyloid formation
Iannuzzi, C., Irace, G., & Sirangelo, I. (2014) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2014.00009 · Cited by 137
Within-patient correspondence of amyloid-β and intrinsic network connectivity in Alzheimer’s disease
Myers, N., Pasquini, L., Göttler, J., Grimmer, T., Koch, K., Ortner, M., Neitzel, J., Mühlau, M., Förster, S., Kurz, A., et al. (2014) · Brain · doi:10.1093/brain/awu103 · Cited by 132
Grothe, M. J., Heinsen, H., Amaro, E., Grinberg, L. T., & Teipel, S. J. (2016) · Cerebral Cortex · doi:10.1093/cercor/bhv062 · Cited by 131
Amyloid-β effects on synapses and memory require AMPA receptor subunit GluA3
Reinders, N. R., Pao, Y., Renner, M. C., da Silva-Matos, C. M., Lodder, T. R., Malinow, R., & Kessels, H. W. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1614249113 · Cited by 128
Paterson, R. W., Slattery, C. F., Poole, T., Nicholas, J. M., Magdalinou, N. K., Toombs, J., Chapman, M. D., Lunn, M. P., Heslegrave, A. J., Foiani, M. S., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0361-3 · Cited by 128
Self-citationAPOE genotype and early β-amyloid accumulation in older adults without dementia
Lim, Y. Y., Mormino, E. C., Initiative, F. T. A. D. N., Initiative, A. D. N., Weiner, M., Aisen, P., Weiner, M., Aisen, P., Petersen, R., Jack, C. R., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004336 · Cited by 125
Self-citationFarrer, L. A. (1997) · JAMA · doi:10.1001/jama.1997.03550160069041 · Cited by 124
Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease
Kerbler, G. M., Fripp, J., Rowe, C. C., Villemagne, V. L., Salvado, O., Rose, S., & Coulson, E. J. (2015) · NeuroImage: Clinical · doi:10.1016/j.nicl.2014.11.015 · Cited by 123
Self-citationWolk, D. A., Zhang, Z., Boudhar, S., Clark, C. M., Pontecorvo, M. J., & Arnold, S. E. (2012) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-302548 · Cited by 122
Kulenkampff, K., Perez, A.-M. W., Sormanni, P., Habchi, J., & Vendruscolo, M. (2021) · Nature Reviews Chemistry · doi:10.1038/s41570-021-00254-9 · Cited by 116
Self-citationYang, T., O’Malley, T. T., Kanmert, D., Jerecic, J., Zieske, L. R., Zetterberg, H., Hyman, B. T., Walsh, D. M., & Selkoe, D. J. (2015) · Alzheimer's Research & Therapy · doi:10.1186/s13195-015-0100-y · Cited by 115
Identification of neurotoxic cross-linked amyloid-β dimers in the Alzheimer’s brain
Brinkmalm, G., Hong, W., Wang, Z., Liu, W., O’Malley, T. T., Sun, X., Frosch, M. P., Selkoe, D. J., Portelius, E., Zetterberg, H., et al. (2019) · Brain · doi:10.1093/brain/awz066 · Cited by 114
Self-citationReduced levels of human apoE4 protein in an animal model of cognitive impairment
Sullivan, P. M., Han, B., Liu, F., Mace, B. E., Ervin, J. F., Wu, S., Koger, D., Paul, S., & Bales, K. R. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.05.011 · Cited by 113
Basal forebrain atrophy is a presymptomatic marker for Alzheimer's disease
Hall, A. M., Moore, R. Y., Lopez, O. L., Kuller, L., & Becker, J. T. (2008) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2008.04.005 · Cited by 112
Single-Molecule Imaging of Individual Amyloid Protein Aggregates in Human Biofluids
Horrocks, M. H., Lee, S. F., Gandhi, S., Magdalinou, N. K., Chen, S. W., Devine, M. J., Tosatto, L., Kjaergaard, M., Beckwith, J. S., Zetterberg, H., et al. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00324 · Cited by 112
APOE*E2 allele delays age of onset in PSEN1 E280A Alzheimer’s disease
Vélez, J. I., Lopera, F., Sepulveda-Falla, D., Patel, H. R., Johar, A. S., Chuah, A., Tobón, C., Rivera, D., Villegas, A., Cai, Y., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.177 · Cited by 111
Johansson, A., Berglind‐Dehlin, F., Karlsson, G., Edwards, K., Gellerfors, P., & Lannfelt, L. (2006) · The FEBS Journal · doi:10.1111/j.1742-4658.2006.05263.x · Cited by 110
Self-citationCavedo, E., Grothe, M. J., Colliot, O., Lista, S., Chupin, M., Dormont, D., Houot, M., Lehéricy, S., Teipel, S., Dubois, B., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-09780-3 · Cited by 109
Self-citationLautner, R., Palmqvist, S., Mattsson, N., Andreasson, U., Wallin, A., Pålsson, E., Jakobsson, J., Herukka, S.-K., Owenius, R., Olsson, B., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1060 · Cited by 107
Self-citationAmyloid Beta and MicroRNAs in Alzheimer’s Disease
Amakiri, N., Kubosumi, A., Tran, J., & Reddy, P. H. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00430 · Cited by 107
Aβ40 and Aβ42 Amyloid Fibrils Exhibit Distinct Molecular Recycling Properties
Sánchez, L., Madurga, S., Pukala, T., Vilaseca, M., López-Iglesias, C., Robinson, C. V., Giralt, E., & Carulla, N. (2011) · Journal of the American Chemical Society · doi:10.1021/ja1117123 · Cited by 105
(2008) · doi:10.1074/jbc.m801487200 · Cited by 105
Self-citationSCHMECHEL, D. E., GOLDGABER, D., BURKHART, D. S., GILBERT, J. R., GAJDUSEK, D. C., & ROSES, A. D. (1988) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-198802020-00002 · Cited by 105
Microglia in Alzheimer’s disease: A target for immunotherapy
Wang, S., & Colonna, M. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.mr0818-319r · Cited by 105 · cited 1×
“Moreover, the dysregulation of microglia activity, including that from dystrophic microglia, may be a trigger and an aggravating factor of the seeding of aberrant protein aggregates in the brain [235, 236].”
BackgroundSpecific Uptake of an Amyloid-β Protofibril-Binding Antibody-Tracer in AβPP Transgenic Mouse Brain
Magnusson, K., Sehlin, D., Syvänen, S., Svedberg, M. M., Philipson, O., Söderberg, L., Tegerstedt, K., Holmquist, M., Gellerfors, P., Tolmachev, V., et al. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-130029 · Cited by 104
Self-citationBasal forebrain atrophy and cortical amyloid deposition in nondemented elderly subjects
Grothe, M. J., Ewers, M., Krause, B., Heinsen, H., & Teipel, S. J. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.09.011 · Cited by 104
(2020) · Brain · doi:10.1093/brain/awaa403 · Cited by 103
Self-citationPreferential degradation of cognitive networks differentiates Alzheimer’s disease from ageing
Chhatwal, J. P., Schultz, A. P., Johnson, K. A., Hedden, T., Jaimes, S., Benzinger, T. L. S., Jack, C., Ances, B. M., Ringman, J. M., Marcus, D. S., et al. (2018) · Brain · doi:10.1093/brain/awy053 · Cited by 101
Self-citationAn, S. S., Cai, Y., & Kim, S. (2015) · Clinical Interventions in Aging · doi:10.2147/cia.s85808 · Cited by 100 · cited 1×
“Mutations in PSEN2 have been reported in association with other diseases, including frontotemporal dementia (FTD), dementia with Lewy bodies (DLB), breast cancer, and dilated cardiomyopathy [38].”
BackgroundSelf-citationSantos, A. N., Ewers, M., Minthon, L., Simm, A., Silber, R.-E., Blennow, K., Prvulovic, D., Hansson, O., & Hampel, H. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-111361 · Cited by 100
Self-citationFreer, R., Sormanni, P., Vecchi, G., Ciryam, P., Dobson, C. M., & Vendruscolo, M. (2016) · Science Advances · doi:10.1126/sciadv.1600947 · Cited by 100
Self-citationPET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET
van Dongen, G. A. M. S., Poot, A. J., & Vugts, D. J. (2012) · Tumor Biology · doi:10.1007/s13277-012-0316-4 · Cited by 98
Engineered antibodies: new possibilities for brain PET?
faculty, O. B. O. T. M., Sehlin, D., & Syvänen, S. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04426-0 · Cited by 96
Chu, J., Lauretti, E., & Praticò, D. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.214 · Cited by 94
Keshavan, A., Pannee, J., Karikari, T. K., Rodriguez, J. L., Ashton, N. J., Nicholas, J. M., Cash, D. M., Coath, W., & Lane, C. A. (2022) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2022-abn.297 · Cited by 94
Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysis
Jansen, W., Ossenkoppele, R., Knol, D., Tijms, B., Scheltens, P., Fr, V., Visser, P. J., Amyloid Biomarker Study Group, Aalten, P., Aarsland, D., et al. (2015) · Archive ouverte UNIGE (University of Geneva) · Cited by 94
Self-citationLord, A., Englund, H., Söderberg, L., Tucker, S., Clausen, F., Hillered, L., Gordon, M., Morgan, D., Lannfelt, L., Pettersson, F. E., et al. (2009) · The FEBS Journal · doi:10.1111/j.1742-4658.2008.06836.x · Cited by 93
Self-citationPereira, J. B., Ossenkoppele, R., Palmqvist, S., Strandberg, T. O., Smith, R., Westman, E., & Hansson, O. (2019) · eLife · doi:10.7554/elife.50830 · Cited by 91
Vingtdeux, V., Hamdane, M., Gompel, M., Bégard, S., Drobecq, H., Ghestem, A., Grosjean, M.-E., Kostanjevecki, V., Grognet, P., Vanmechelen, E., et al. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.05.004 · Cited by 88
Toledo, J. B., Bjerke, M., Da, X., Landau, S. M., Foster, N. L., Jagust, W., Jack, C., Weiner, M., Davatzikos, C., Shaw, L. M., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4829 · Cited by 88
Role of common and rare APP DNA sequence variants in Alzheimer disease
Hooli, B. V., Mohapatra, G., Mattheisen, M., Parrado, A. R., Roehr, J. T., Shen, Y., Gusella, J. F., Moir, R., Saunders, A. J., Lange, C., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182515972 · Cited by 87
Neutralization of TNFSF10 ameliorates functional outcome in a murine model of Alzheimer’s disease
Cantarella, G., Di Benedetto, G., Puzzo, D., Privitera, L., Loreto, C., Saccone, S., Giunta, S., Palmeri, A., & Bernardini, R. (2015) · Brain · doi:10.1093/brain/awu318 · Cited by 86
Torrisi, S. A., Geraci, F., Tropea, M. R., Grasso, M., Caruso, G., Fidilio, A., Musso, N., Sanfilippo, G., Tascedda, F., Palmeri, A., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00693 · Cited by 86
The dynamics of biomarkers across the clinical spectrum of Alzheimer's disease
Hadjichrysanthou, C., Evans, S., Bajaj, S., Siakallis, L. C., McRae-McKee, K., de Wolf, F., Anderson, R. M., & Initiative, T. A. D. N. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00636-z · Cited by 86
Lim, Y. Y., Kalinowski, P., Pietrzak, R. H., Laws, S. M., Burnham, S. C., Ames, D., Villemagne, V. L., Fowler, C. J., Rainey-Smith, S. R., Martins, R. N., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.4325 · Cited by 84
Self-citationAlsema, A. M., Jiang, Q., Kracht, L., Gerrits, E., Dubbelaar, M. L., Miedema, A., Brouwer, N., Hol, E. M., Middeldorp, J., van Dijk, R., et al. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00134 · Cited by 84
Beach, T. G., Honer, W. G., & Hughes, L. H. (1997) · Acta Neuropathologica · doi:10.1007/s004010050595 · Cited by 83
Tharp, W. G., & Sarkar, I. (2013) · BMC Genomics · doi:10.1186/1471-2164-14-290 · Cited by 82
Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease
Aisen, P. S. S., Vellas, B. J., & Hampel, H. J. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3842-c1 · Cited by 81
Self-citationConcordance of Lumipulse cerebrospinal fluid t‐tau/Aβ42 ratio with amyloid PET status
Kaplow, J., Vandijck, M., Gray, J., Kanekiyo, M., Huyck, E., Traynham, C. J., Esquivel, R., Fagan, A. M., & Luthman, J. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12000 · Cited by 81
GSK-3α/β kinases and amyloid production in vivo
Jaworski, T., Dewachter, I., Lechat, B., Gees, M., Kremer, A., Demedts, D., Borghgraef, P., Devijver, H., Kügler, S., Patel, S., et al. (2011) · Nature · doi:10.1038/nature10615 · Cited by 79
Spatially distinct atrophy is linked to β-amyloid and tau in preclinical Alzheimer disease
Wang, L., Benzinger, T. L., Hassenstab, J., Blazey, T., Owen, C., Liu, J., Fagan, A. M., Morris, J. C., & Ances, B. M. (2015) · Neurology · doi:10.1212/wnl.0000000000001401 · Cited by 79
Zimbone, S., Monaco, I., Gianì, F., Pandini, G., Copani, A. G., Giuffrida, M. L., & Rizzarelli, E. (2018) · Aging Cell · doi:10.1111/acel.12684 · Cited by 79 · cited 1×
“a set of activity-dependent and adaptive structural/functional changes in synaptic strength or efficacy) [132, 133].”
BackgroundZhang, Y., Guo, O., Huo, Y., Wang, G., & Man, H.-Y. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170879 · Cited by 77
Hampel, H., Shaw, L. M., Aisen, P., Chen, C., Lleó, A., Iwatsubo, T., Iwata, A., Yamada, M., Ikeuchi, T., Jia, J., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12372 · Cited by 77 · cited 22×
“The CSF tau/Aβ1-42 ratio represents a reliable tool for predicting cognitive decline in nondemented older adults and individuals with subjective cognitive decline, a risk factor for AD [324–326].”
BackgroundInfluentialSelf-citationCarter, T. L., Rissman, R. A., Mishizen-Eberz, A. J., Wolfe, B. B., Hamilton, R. L., Gandy, S., & Armstrong, D. M. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2003.12.010 · Cited by 76
High detection sensitivity with antibody-based PET radioligand for amyloid beta in brain
Fang, X. T., Hultqvist, G., Meier, S. R., Antoni, G., Sehlin, D., & Syvänen, S. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2018.10.011 · Cited by 76
Brännström, K., Öhman, A., Nilsson, L., Pihl, M., Sandblad, L., & Olofsson, A. (2014) · Journal of the American Chemical Society · doi:10.1021/ja503535m · Cited by 74
Innate immune activation in Alzheimer’s disease
Wang, M.-M., Miao, D., Cao, X.-P., Tan, L., & Tan, L. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.04.20 · Cited by 72
Autophagy-mediated Regulation of BACE1 Protein Trafficking and Degradation
Feng, T., Tammineni, P., Agrawal, C., Jeong, Y. Y., & Cai, Q. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.766584 · Cited by 69
Modulation of γ- and β-secretases as early prevention against Alzheimer's disease
Voytyuk, I., De Strooper, B., & Chávez-Gutiérrez, L. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.001 · Cited by 67
Plasma amyloid-β oligomers level is a biomarker for Alzheimer’s disease diagnosis
Zhou, L., Chan, K. H., Chu, L., Kwan, J., Song, Y., Chen, L. H., Ho, P. W., Cheng, O., Ho, J. W.-M., & Lam, K. S. L. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.06.017 · Cited by 63
Sahlin, C., Lord, A., Magnusson, K., Englund, H., Almeida, C. G., Greengard, P., Nyberg, F., Gouras, G. K., Lannfelt, L., & Nilsson, L. N. G. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04443.x · Cited by 62
Self-citationEspada, S., Rojo, A. I., Salinas, M., & Cuadrado, A. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06208.x · Cited by 62
Clinical Heterogeneity of Probable Alzheimer's Disease
Blennow, K., & Wallin, A. (1992) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/002383099200500208 · Cited by 62 · cited 1×
“Conversely, BBB anatomical disruption and functional breakdown may be detrimental for Aβ homeostasis as a part of early pathophysiological alterations in AD individuals [138].”
BackgroundSelf-citationKidana, K., Tatebe, T., Ito, K., Hara, N., Kakita, A., Saito, T., Takatori, S., Ouchi, Y., Ikeuchi, T., Makino, M., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708184 · Cited by 61
Self-citationOrigin of the PSEN1 E280A mutation causing early‐onset Alzheimer's disease
Lalli, M. A., Cox, H. C., Arcila, M. L., Cadavid, L., Moreno, S., Garcia, G., Madrigal, L., Reiman, E. M., Arcos‐Burgos, M., Bedoya, G., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.09.005 · Cited by 60
Söllvander, S., Ekholm-Pettersson, F., Brundin, R.-M., Westman, G., Kilander, L., Paulie, S., Lannfelt, L., & Sehlin, D. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150236 · Cited by 60
Self-citationSyvänen, S., Fang, X. T., Hultqvist, G., Meier, S. R., Lannfelt, L., & Sehlin, D. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2017.01.004 · Cited by 58
Self-citationAβ amyloid, cognition, and APOE genotype in healthy older adults
Lim, Y. Y., Ellis, K. A., Ames, D., Darby, D., Harrington, K., Martins, R. N., Masters, C. L., Rowe, C., Savage, G., Szoeke, C., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.07.004 · Cited by 57
Self-citationβ-Amyloid oligomers in aging and Alzheimer’s disease
Zahs, K. R., & Ashe, K. H. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00028 · Cited by 53
Giuffrida, M. L., Tomasello, M. F., Pandini, G., Caraci, F., Battaglia, G., Busceti, C., Di Pietro, P., Pappalardo, G., Attanasio, F., Chiechio, S., et al. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00297 · Cited by 52
Wang, Y.-H., Zhu, T.-R., Wang, M., Zhang, F., Zhang, G., Zhao, J., Zhang, Y.-Y., Wu, E., & Li, X.-H. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00291 · Cited by 52
Teipel, S. J., Cavedo, E., Hampel, H., Grothe, M. J., Initiative, A. D. N., & (APMI), A. P. M. I. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00642 · Cited by 49
Self-citationAβ42 Protofibrils Interact with and Are Trafficked through Microglial-Derived Microvesicles
Gouwens, L. K., Ismail, M. S., Rogers, V. A., Zeller, N. T., Garrad, E. C., Amtashar, F. S., Makoni, N. J., Osborn, D. C., & Nichols, M. R. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00029 · Cited by 48
Hampel, H., Lista, S., Neri, C., & Vergallo, A. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101662 · Cited by 47
Self-citationHampton, O. L., Buckley, R. F., Manning, L. K., Scott, M. R., Properzi, M. J., Peña-Gómez, C., Jacobs, H. I. L., Chhatwal, J. P., Johnson, K. A., Sperling, R. A., et al. (2020) · NeuroImage Clinical · doi:10.1016/j.nicl.2020.102407 · Cited by 47
Good gene, bad gene: New APP variant may be both
Fede, G. D., Catania, M., Morbin, M., Giaccone, G., Moro, M. L., Ghidoni, R., Colombo, L., Messa, M., Cagnotto, A., Romeo, M., et al. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.06.004 · Cited by 46
Estimating dementia cases amongst migrants living in Europe
Canevelli, M., Lacorte, E., Cova, I., Zaccaria, V., Valletta, M., Raganato, R., Bruno, G., Bargagli, A. M., Pomati, S., Pantoni, L., et al. (2019) · European Journal of Neurology · doi:10.1111/ene.13964 · Cited by 46
Zou, L.-B., Mouri, A., Iwata, N., Saido, T. C., Wang, D., Wang, M., Mizoguchi, H., Noda, Y., & Nabeshima, T. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.095687 · Cited by 45
Cissé, M., Braun, U., Leitges, M., Fisher, A., Pagès, G., Checler, F., & Vincent, B. (2011) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2011.04.008 · Cited by 45
Pittsburgh Compound‐B (PiB) binds amyloid β‐protein protofibrils
Yamin, G., & Teplow, D. B. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.13887 · Cited by 44
Chiesa, P. A., Cavedo, E., Grothe, M. J., Houot, M., Teipel, S. J., Potier, M.-C., Habert, M.-O., Lista, S., Dubois, B., Hampel, H., et al. (2019) · Radiology · doi:10.1148/radiol.2018180268 · Cited by 42
Self-citationNyarko, J. N. K., Quartey, M. O., Pennington, P. R., Heistad, R. M., Dea, D., Poirier, J., Baker, G. B., & Mousseau, D. D. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.01.005 · Cited by 41
Astrocytes contain amyloid-β annular protofibrils in Alzheimer's disease brains
Lasagna-Reeves, C. A., & Kayed, R. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.08.027 · Cited by 40
Parker, T. D., Cash, D. M., Lane, C., Lu, K., Malone, I. B., Nicholas, J. M., James, S., Keshavan, A., Murray‐Smith, H., Wong, A., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0224030 · Cited by 40
The role of post-translational modification in ϐ-amyloid precursor protein processing
Georgopoulou, N., McLaughlin, M., McFarlane, I., & Breen, K. C. (2001) · Biochemical Society Symposia · doi:10.1042/bss0670023 · Cited by 39
Farizatto, K. L. G., Ikonne, U. S., de Almeida, M. F., Ferrari, M., & Bahr, B. A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182895 · Cited by 38
Teipel, S. J., Dyrba, M., Chiesa, P. A., Sakr, F. A., Jelistratova, I., Lista, S., Vergallo, A., Lemercier, P., Cavedo, E., Habert, M. O., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.03.011 · Cited by 38
Self-citationAβ-related memory decline in APOE ε4 noncarriers: Implications for Alzheimer disease
Lim, Y. Y., Laws, S. M., Villemagne, V. L., Pietrzak, R. H., Porter, T., Ames, D., Fowler, C., Rainey-Smith, S., Snyder, P. J., Martins, R. N., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002604 · Cited by 37
Self-citationAn, S. S. A., Lim, K., Oh, H. J., Lee, B., Zukic, E., Ju, Y. R., Yokoyama, T., Kim, S. Y., & Welker, E. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.01.053 · Cited by 35
Self-citationAmyloid-β42 protofibrils are internalized by microglia more extensively than monomers
Gouwens, L. K., Makoni, N. J., Rogers, V. A., & Nichols, M. R. (2016) · Brain Research · doi:10.1016/j.brainres.2016.08.016 · Cited by 35
Structure and Function of Alzheimer’s Amyloid βeta Proteins from Monomer to Fibrils: A Mini Review
Agrawal, N., & Skelton, A. A. (2019) · The Protein Journal · doi:10.1007/s10930-019-09854-3 · Cited by 35
Kunkle, B., Grenier-Boley, B., Sims, R., Bis, J., Naj, A., Boland, A., Vronskaya, M., van der Lee, S., Amlie-Wolf, A., Bellenguez, C., et al. (2018) · doi:10.1101/294629 · Cited by 35
Self-citationThe Off-rate of Monomers Dissociating from Amyloid-β Protofibrils
Grüning, C. S. R., Klinker, S., Wolff, M., Schneider, M., Toksöz, K., Klein, A. N., Nagel‐Steger, L., Willbold, D., & Hoyer, W. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.513432 · Cited by 34
Presenilin-1 Protects against Neuronal Apoptosis Caused by Its Interacting Protein PAG
Zhou, Y., Zhang, W., Easton, R., Ray, J. W., Lampe, P. A., Jiang, Z., Brunkan, A. L., Goate, A., Johnson, E. M., & Wu, J. Y. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0472 · Cited by 33
A Strategy for Combating Melanoma with Oncogenic c-Myc Inhibitors and Targeted Nanotherapy
Pan, D., Kim, B. B., Hu, G., Gupta, D. S., Senpan, A., Yang, X., Schmieder, A. H., Swain, C., Wickline, S. A., Tomasson, M. H., et al. (2015) · Nanomedicine · doi:10.2217/nnm.14.101 · Cited by 32
ADAM10 Prodomain Mutations Cause Late-Onset Alzheimer’s Disease: Not Just the Latest FAD
Vassar, R. (2013) · Neuron · doi:10.1016/j.neuron.2013.09.031 · Cited by 32
Xu, G. M., Fromholt, S., Chakrabarty, P., Zhu, F., Liu, X., Pace, M. C., Koh, J., Golde, T. E., Levites, Y., Lewis, J. M., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00911-y · Cited by 32
Leuzy, A., Zimmer, E. R., Heurling, K., Rosa-Neto, P., & Gauthier, S. (2014) · Amyloid · doi:10.3109/13506129.2014.926267 · Cited by 31
Anti-microRNAs as Novel Therapeutic Agents in the Clinical Management of Alzheimer's Disease
Zhao, Y., Alexandrov, P. N., & Lukiw, W. J. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00059 · Cited by 30 · cited 1×
“MicroRNAs (miRNAs) constitute a large family of small noncoding RNAs that exert an inhibitory effect on gene expression by destabilizing messenger RNAs and inhibiting the translation process [93].”
BackgroundLai, M. K. P., Tsang, S. W. Y., Garcia-Alloza, M., Minger, S. L., Nicoll, J. A. R., Esiri, M. M., Wong, P. T.-H., Chen, C. P. L.-H., Ramírez, M. J., & Francis, P. T. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.12.016 · Cited by 29
Self-citationUptake of Aβ 1–40- and Aβ 1–42-coated yeast by microglial cells: a role for LRP
Laporte, V., Lombard, Y., Levy-Benezra, R., Tranchant, C., Poindron, P., & Warter, J.-M. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.1203620 · Cited by 27
Santos, A. N., Simm, A., Holthoff‐Detto, V., & Boehm, G. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14201 · Cited by 24
Falzi, M., & Gm, B. (1969) · PubMed · Cited by 22
γ-Secretase Activity Is Associated with Braak Senile Plaque Stages
Kakuda, N., Yamaguchi, H., Akazawa, K., Hata, S., Suzuki, T., Hatsuta, H., Murayama, S., Funamoto, S., & Ihara, Y. (2020) · American Journal Of Pathology · doi:10.1016/j.ajpath.2020.02.009 · Cited by 22
Zou, Mouri, Iwata, Saido, Wang, Mw, Mizoguchi, Noda, & Nabeshima (2006) · 中国生物学文摘 · Cited by 22
Research works printed but not linked: 1
- Yamashita K Hasegawa T Iino T Miura M Watanabe T Watanabe S P075-prediction of amyloid pathology by the plasma Aβ(1-42)/Aβ(1-40) ratio measured with fully automated immunoassay system (HISCL™ SERIES) J Prev Alz Dis 2019 6 S89
Cited by
Lecanemab in early Alzheimer's disease
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678
Self-citationZhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“83,423 The disparity in drug performance between preclinical and human trials has driven the evolution of animal models.”
BackgroundAmyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future
Zhang, Y., Chen, H., Li, R., Sterling, K., & Song, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01484-7 · Cited by 988
Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology
Ashton, N. J., Brum, W. S., Di Molfetta, G., Benedet, A. L., Arslan, B., Jonaitis, E., Langhough, R. E., Cody, K., Wilson, R., Carlsson, C. M., et al. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2023.5319 · Cited by 884
Self-citationClinical applications of stem cell-derived exosomes
Tan, F., Li, X., Wang, Z., Li, J., Shahzad, K., & Zheng, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01704-0 · Cited by 708
Metadata
- Authors
- Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., Masters, C. L., Cho, M., Lannfelt, L., Cummings, J. L., & Vergallo, A.
- Affiliations
- Eisai (United States) (US)
- UK Dementia Research Institute (GB)
- Sahlgrenska University Hospital (SE)
- National University of Singapore (SG)
- The University of Texas at San Antonio (US)
- Hanyang University Seoul Hospital (KR)
- The University of Melbourne (AU)
- University of Southern California (US)
- University of Cambridge (GB)
- The University of Tokyo (JP)
- Uppsala University (SE)
- University of Nevada, Las Vegas (US)
- Corresponding author
- Hampel, Harald
- Vergallo, Andrea
- ORCID
- Venue
- Molecular Psychiatry
- Published
- 2021-08-30
- Volume
- 26
- Issue
- 10
- Pages
- 5481-5503
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- PMC
- PMC8758495
- OpenAlex
- W3198052269
- Cited by
- 1,952
- References
- 418
- Citations by year
- 2026: 451 · 2025: 608 · 2024: 468 · 2023: 297 · 2022: 113 · 2021: 15
- FWCI
- 30.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Molecular Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Scholarship - UNLV (University of Nevada Reno) (submittedVersion, cc-by)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- National University of Singapore (submittedVersion)
- Uppsala University Publications (Uppsala University) (submittedVersion, other-oa)
- HAL (submittedVersion, other-oa)
- UCL Discovery (University College London) (submittedVersion)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- Molecular Psychiatry
- Apollo
- Funders
- Alzheimer’s Drug Discovery Foundation (RDAPB-201809-2016615)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta, Alzheimer's disease, tau protein, neuroinflammation, neurodegeneration, synaptic failure, multimodal biomarkers, in vivo biomarkers, disease-modifying therapy, early treatment
- MeSH terms
- Alzheimer Disease, Humans, Biomarkers, Amyloid beta-Peptides, tau Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.